- A new TGA-approved rapid antigen test will add Respiratory Syncytial Virus (RSV) to the list of viruses Australians can self-test for with a single swab.
- The self-testing nasal swab diagnoses three different viruses accurately within 15 minutes.
- Developed by Touch Biotechnology, the combination test is available now and will help combat the spread of COVID-19, Influenzas A and B and Respiratory Syncytial Virus (RSV).
As Australia heads into flu season, health experts are warning the public about the looming ‘Triple Threat Virus’. The risk of severe illness due to the flu, COVID-19, and Respiratory Syncytial Virus (RSV) co-infections is a growing concern. However, Australians can now self-test for all three following the Therapeutic Goods Administration’s (TGA) approval of a new Triple Combo Rapid Antigen Test.
Resembling a mild cold, RSV can cause breathing and lung problems like bronchiolitis and pneumonia. Concerningly, it is very infectious and largely effects over 65s with vulnerable immune systems(2) and children under three years are at the highest risk of serious illness.(3)
In response to the growing concern for co-infections and to help protect vulnerable community members, Australian-based developer and manufacturer, Touch Biotechnology, has released the First TGA-approved multi-virus diagnostic testing kits in the Australian market (ARTG Number: 408459). This cutting-edge diagnostic solution will empower people to take control of their health by providing unparalleled convenience, sensitivity, and accuracy in detecting RSV, Flu A/B, and COVID-19 infections at home.
Akin to the RAT tests we’ve become accustomed to, the Triple Combo Test boasts a sensitivity rate for all three viruses and an accuracy rate of over 98%. Utilising a similar process, through a single nasal swab, results are available within 15 minutes, allowing users to obtain accurate and timely information about their health status.
Australians are recommended to take a Triple Combo Rapid Antigen Test for RSV, Flu, and COVID-19 when they feel unwell, have any symptoms or have been in contact with someone who has these viruses. The RSV, Flu A/B, and Covid Rapid Antigen Test for Self-Testing will be available to purchase at retail stores and online. For more information, please visit: www.touchaustralia.com.au
About the Research & Citations
About Touch Biotechnology
Founded in 2020 in Sydney, Australia, Touch Biotechnology is one of the leading manufacturers and developers of advanced antimicrobial protection solutions and rapid in-vitro antigen tests. It is dedicated to developing solutions that are evidently effective, and continually demonstrates a commitment to building products that have a positive impact on human lives, while remaining socially and environmentally responsible.
Text by: Touch Biotechnology